$COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Andrew R. Robbins
CEO
205
Employees
$35.21
Current Price
$5.66B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $242,620,000.00 | 7,000,000 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $242,620,000.00 | 7,000,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $242,620,000.00 | 7,000,000 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $370,020,000.00 | 10,500,000 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Sale | 7,000,000 | $34.66 | $242,620,000.00 | View Details |
| Jan 22, 2026 | Fairmount Funds Management LLC Director | Sale | 3,500,000 | $36.40 | $127,400,000.00 | View Details |
5 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.51
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: